NCT00231777View on ClinicalTrials.gov

A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)

PHASE3CompletedINTERVENTIONAL

Enrollment

216

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Post-Operative Nausea and Vomiting

Interventions

DRUG

Comparator: MK0517

a single administration of 40 mg MK0517 by IV immediately prior to surgery

DRUG

Comparator: ondansetron

a single administration of 4 mg ondansetron by IV immediately prior to surgery

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00231777 - A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015) | Biotech Hunter | Biotech Hunter